Y-mAbs anticipates a reduction in its current workforce of up to approximately 13%.
All entries for: Small Molecule
January 10, 2025
Y-mAbs Therapeutics
Layoffs
New York, NY
51-200 employees
Disease Area: Rare Diseases
Drug Type: Biologic, Small Molecule
January 10, 2025
Passage Bio
Layoffs
Philadelphia, PA
51-200 employees
This transition, coupled with an associated reduction in workforce of approximately 55% and reductions in operating expenses, is expected to extend cash runway into the first quarter of 2027.
Disease Area: Rare Diseases
Drug Type: Biologic, Small Molecule
January 9, 2025
IGM Biosciences
Layoffs
Mountain View, CA
201-500 employees
Company is immediately taking steps, including an approximately 73% reduction in workforce, to preserve cash.
Disease Area: Rare Diseases
Drug Type: Biologic, Small Molecule
January 9, 2025
Intellia Therapeutics
Layoffs
Cambridge, MA
501-1,000 employees
Anticipated cost savings, including a net workforce reduction of approximately 27% in 2025, support company operations into 1H 2027 and through anticipated, first commercial launch in the U.S.
Disease Area: Rare Diseases
Drug Type: Biologic, Small Molecule
January 8, 2025
Galapagos
Discontinued Research, Layoffs
Cambridge, MA
1,001-5,000 employees
“To advance its goal of becoming a global leader in cell therapy in oncology, Galapagos plans to discontinue its small molecule discovery programs and seek potential partners to take over its small molecules’ assets, including the TYK2 inhibitor, GLPG3667, currently in Phase 2 for systemic lupus erythematosus, dermatomyositis, and other potential auto-immune indications.”
2 Discontinued Research Programs
Disease Area: Chronic Disease, Immune Diseases, Multiple
Drug Type: Small Molecule
January 8, 2025
Galapagos
Layoffs
Cambridge, MA
1,001-5,000 employees
Galapagos intends to reorganize its business to focus on long-term value creation in cell therapy in oncology. This is anticipated to lead to a reduction of approximately 300 positions.
Disease Area: Rare Diseases
Drug Type: Biologic, Small Molecule
December 31, 2024
Kiora Pharmaceuticals
Negative Outlook
Encinitas, CA
1-50 employees
“Current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product.”
Disease Area: Rare Diseases
Drug Type: Biologic, Small Molecule
December 10, 2024
Belharra Therapeutics
Layoffs
San Diego, CA
1-50 employees
“San Diego startup Belharra Therapeutics, a biotech creating small molecule cancer and immunology medicines, has laid off 21 employees, Endpoints News has confirmed…
The employee cuts are expected to allow Belharra to extend its runway to achieve “key inflection points” while alleviating capital raise pressures, according to a spokesperson’s emailed statement to Endpoints. That spokesperson also wrote that the biotech will continue advancing its lead programs and working with partners Genentech and Sanofi.”
Disease Area: Immune Diseases, Multiple, Oncology
Drug Type: Small Molecule
December 9, 2024
AmplifyBio
Layoffs
West Jefferson, OH
201-500 employees
“AmplifyBio is cutting costs, closing its R&D and characterization services site in South San Francisco and laying off employees in its Ohio-based preclinical CRO business, a company spokesperson confirmed to Fierce Biotech in an email.”
Disease Area: Cardiology, Neurological Diseases, Respiratory Diseases
Drug Type: Biologic, Small Molecule
December 9, 2024
Neuren Pharmaceuticals
Discontinued Drug, Discontinued Research
Camberwell, Australia
1-50 employees
At the end of 2024, Neuren Pharmaceuticals Limited announced the suspension of its Phase II open-label study of the safety, tolerability, and pharmacokinetics of oral NNZ-2591 in Prader-Willi syndrome (PWS-001) due to a revised development strategy.
1 Discontinued Drug: NNZ-2591 for treatment of Prader-Willi Syndrome
1 Discontinued Research Program
Disease Area: Rare Diseases
Drug Type: Small Molecule
